Arora Sukeshi Patel, Liposits Gabor, Caird Susan, Dunne Richard F, Moffat Gordon Taylor, Okonji David, Rodriquenz Maria Grazia, Dua Divyanshu, Dotan Efrat
Mays Cancer Center, University of Texas Health San Antonio, Leader in Gastrointestinal Malignancies, 7979 Wurzbach Rd, 78229 San Antonio, TX, USA.
Region Hospital West Jutland, Herning, Denmark.
J Geriatr Oncol. 2020 May;11(4):557-565. doi: 10.1016/j.jgo.2019.10.007. Epub 2019 Nov 6.
Given the prevalence and the rising incidence of hepatocellular carcinoma (HCC) in older adults worldwide, there is an urgent need to improve our understanding of the implications of treatment modalities in this population. The care of older patients with HCC is challenging due to the lack of evidence-based recommendations in this population. The current treatment approach for older patients relies on extrapolation of data from clinical trials conducted mostly in younger patients or fit older adults. Further, in the last few years, the arsenal of systemic treatments has increased with currently seven FDA-approved therapies available for patients with advanced HCC. Therefore, understanding how to apply current data to this unique and diverse patient population is necessary. This review will aim to shed light on the approach to older adults with HCC through an assessment of available data in the literature.
鉴于全球范围内老年人群肝细胞癌（HCC）的患病率和发病率不断上升，迫切需要加深我们对该人群治疗方式影响的理解。由于该人群缺乏循证医学推荐，老年HCC患者的护理颇具挑战性。目前针对老年患者的治疗方法主要依赖于大多在年轻患者或健康老年人群中开展的临床试验数据推断。此外，在过去几年中，全身治疗手段有所增加，目前有七种FDA批准的疗法可用于晚期HCC患者。因此，有必要了解如何将现有数据应用于这一独特且多样的患者群体。本综述旨在通过评估文献中的现有数据，阐明老年HCC患者的治疗方法。
